Providing a VOICE for Texas' MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1988
Meetings & Education
Bolstering Patient Care with Decision Support Tools
Patient Advocacy Organizations
TxSCO Hurricane Harvey Recovery Resources
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
TxSCO Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Pembrolizumab for Advanced Cervical Cancer
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Read the full FDA press release here.
Tweets by OSSatACCC